Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214


3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.


Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.

Draht MXG, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V, Smits KM.

Clin Epigenetics. 2018 Mar 14;10:35. doi: 10.1186/s13148-018-0461-8. eCollection 2018. Review.


Individualized prediction of perineural invasion in colorectal cancer: development and validation of a radiomics prediction model.

Huang Y, He L, Dong D, Yang C, Liang C, Chen X, Ma Z, Huang X, Yao S, Liang C, Tian J, Liu Z.

Chin J Cancer Res. 2018 Feb;30(1):40-50. doi: 10.21147/j.issn.1000-9604.2018.01.05.


Distribution of Lymph Nodes in Stage III Patients With Mid and Low Rectal Cancer: Preliminary Study.

Kim S.

Ann Coloproctol. 2018 Feb;34(1):42-46. doi: 10.3393/ac.2018.34.1.42. Epub 2018 Feb 28.


Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer.

Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R, Emami MH.

Adv Biomed Res. 2018 Feb 16;7:28. doi: 10.4103/abr.abr_185_16. eCollection 2018. Review.


Association of Genetic Variants of Small Non-Coding RNAs with Survival in Colorectal Cancer.

Pao JB, Lu TL, Ting WC, Chen LM, Bao BY.

Int J Med Sci. 2018 Jan 1;15(3):217-222. doi: 10.7150/ijms.22402. eCollection 2018.


Lymph node retrieval after dissolution of surrounding adipose tissue for pathological examination of colorectal cancer.

Maeda H, Okamoto K, Oba K, Shiga M, Fujieda Y, Namikawa T, Hiroi M, Murakami I, Hanazaki K, Kobayashi M.

Oncol Lett. 2018 Feb;15(2):2495-2500. doi: 10.3892/ol.2017.7629. Epub 2017 Dec 14.


Sialyl Lewisx expression at the invasive front as a predictive marker of liver recurrence in stage II colorectal cancer.

Yamadera M, Shinto E, Tsuda H, Kajiwara Y, Naito Y, Hase K, Yamamoto J, Ueno H.

Oncol Lett. 2018 Jan;15(1):221-228. doi: 10.3892/ol.2017.7340. Epub 2017 Nov 3.


Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/β-catenin signaling.

Zhang K, Li M, Huang H, Li L, Yang J, Feng L, Gou J, Jiang M, Peng L, Chen L, Li T, Yang P, Yang Y, Wang Y, Peng Q, Dai X, Zhang T.

Oncotarget. 2017 Dec 14;8(70):115803-115816. doi: 10.18632/oncotarget.23253. eCollection 2017 Dec 29.


Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.

Li Z, Huang Y, Zhao R, Cui Y, Zhou Y, Wu X.

Sci Rep. 2018 Jan 11;8(1):510. doi: 10.1038/s41598-017-19001-6.


Significance of the E3 ubiquitin protein UBR5 as an oncogene and a prognostic biomarker in colorectal cancer.

Xie Z, Liang H, Wang J, Xu X, Zhu Y, Guo A, Shen X, Cao F, Chang W.

Oncotarget. 2017 Nov 20;8(64):108079-108092. doi: 10.18632/oncotarget.22531. eCollection 2017 Dec 8.


S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.

Ann Oncol. 2018 Mar 1;29(3):624-631. doi: 10.1093/annonc/mdx816.


Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.

Kashif M, Andersson C, Mansoori S, Larsson R, Nygren P, Gustafsson MG.

Oncotarget. 2017 Oct 19;8(61):103952-103967. doi: 10.18632/oncotarget.21895. eCollection 2017 Nov 28.


Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer.

Ochoa-Callejero L, García-Sanmartín J, Martínez-Herrero S, Rubio-Mediavilla S, Narro-Íñiguez J, Martínez A.

Sci Rep. 2017 Dec 13;7(1):17488. doi: 10.1038/s41598-017-17573-x.


Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.

Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, Kanda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T.

J Cancer. 2017 Oct 23;8(19):4057-4064. doi: 10.7150/jca.21365. eCollection 2017.


Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.

Liu Y, Meucci S, Sheng L, Keilholz U.

Oncotarget. 2017 May 26;8(44):77928-77941. doi: 10.18632/oncotarget.18272. eCollection 2017 Sep 29.


Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance.

Pang LY, Saunders L, Argyle DJ.

Oncotarget. 2017 Aug 3;8(42):72494-72512. doi: 10.18632/oncotarget.19868. eCollection 2017 Sep 22.


International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.

van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB.

Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.


Supplemental Content

Support Center